Assessing the Impact of Simplified Language on a Patient-Facing Pharmacogenetic Report: A User Comprehension Study
Journal of Personalized Medicine · 12.06.2025 · 15 (6) · 247
DOI: 10.3390/jpm15060247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 12.06.2025. Verfasst von Russell Amato und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research & Development and Medical Affairs, Genomind, Inc., King of Prussia, PA 19406, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHGRI NIH HHS, National Human Genome Research Institute of the National Institutes of Health.
Abstract (Originalsprache)
Background
Pharmacogenetics (PGx) is the science of assessing how genetic variation affects drug efficacy, tolerability, and safety. While PGx is an emerging discipline which is becoming standard of care, many providers have misunderstandings about its utility. This is even more of a problem for patients, who may perceive that there is a single drug that is “right” for them. The primary objective of this study was to evaluate consumer comprehension of a newly developed patient-facing PGx report.
Methods
In this study, we adapted a commercial pharmacogenetic test (Genomind Professional PGx) into a report intended to be more comprehensible to the consumer. The initial translation of the clinical terminology used in the PGx report, into lay terminology was conducted by PharmDs and PhDs who have collectively provided over 20,000 PGx consults to date. These reports were then evaluated with readability scoring software to ensure each translation’s complexity remained ≤8th-grade reading level. A total of 107 participants were recruited to conduct the initial analysis with a goal of achieving a 90% comprehension rate using the Genomind consumer comprehension survey. These participants were also given a modified Minnesota Assessment of Pharmacogenomic Literacy (MAPL™) both before and after the Genomind comprehension survey to assess overall PGx literacy.
Results
Ninety-eight (98) out of 107 research participants scored one or zero questions incorrectly, translating to >90% comprehension score on the Genomind consumer comprehension survey. These participants also demonstrated a significant increase in overall pharmacogenetic literacy, as assessed by MAPL after viewing the consumer report and survey.
Conclusions
This study found that translating pharmacogenetic test results into lay language may provide individuals with a greater understanding of how their DNA may impact prescribed medications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Research & Development and Medical Affairs, Genomind, Inc., King of Prussia, PA 19406, USA.
ORCID-Profile: Russell Amato, Nicole M Del Toro-Pagan, Jordan Plummer, Daniel Dowd
Förderung
- NHGRI NIH HHS
- National Human Genome Research Institute of the National Institutes of Health
Zitieren
APA
Amato, R., Del Toro-Pagan, N. M., Nguyen, H., Plummer, J., Pizzolato, K., Krause, D., & Dowd, D. (2025). Assessing the Impact of Simplified Language on a Patient-Facing Pharmacogenetic Report: A User Comprehension Study. Journal of Personalized Medicine, 15(6), 247. https://doi.org/10.3390/jpm15060247
Vancouver
Amato R, Del Toro-Pagan NM, Nguyen H, Plummer J, Pizzolato K, Krause D, et al. Assessing the Impact of Simplified Language on a Patient-Facing Pharmacogenetic Report: A User Comprehension Study. Journal of Personalized Medicine. 2025;15(6):247. doi:10.3390/jpm15060247
BibTeX
@article{Amato2025,
author = {Amato, Russell and Del Toro-Pagan, Nicole M and Nguyen, Harris and Plummer, Jordan and Pizzolato, Katie and Krause, David and Dowd, Daniel},
title = {Assessing the Impact of Simplified Language on a Patient-Facing Pharmacogenetic Report: A User Comprehension Study},
journal = {Journal of Personalized Medicine},
year = {2025},
volume = {15},
number = {6},
pages = {247},
doi = {10.3390/jpm15060247}
}
EUVIMED